What is the stock symbol for Haemonetics?
Key Data. Open $55.85. Day Range 53.51 - 55.85. 52 Week Range 43.50 - 121.99. Market Cap $2.75B. Shares Outstanding 51.11M. Public Float 50.64M. Beta …
How much of Haemonetics'stock is owned by insiders?
Apr 03, 2022 · Haemonetics' stock was trading at $103.72 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HAE stock has decreased by 42.3% and is now trading at $59.82. View …
What are Haemonetics'price targets for the next 12 months?
5 rows · HAE. $63.85 $0.63 1.0%. Price as of April 1, 2022, 4:00 p.m. ET View Interactive HAE Charts. ...
What do investors think about Haemonetics (Hae)?
Haemonetics Corp. 56.42. Delayed Data. As of 4:00pm ET. -0.97 / -1.69%. Today’s Change. 43.50. Today ||| 52-Week Range. 75.34.
Is hae a good stock?
Haemonetics has received a consensus rating of Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.
Will Haemonetics stock go back up?
We believe that HAE stock will rebound in the near term, given the company's positive outlook for fiscal 2022, with revenue growth of 10% and EPS growth of 19% at the mid-point of the provided guidance, primarily led by a recovery in demand as the Covid-19 crisis winds down.Sep 23, 2021
Will Hae stock go up?
Given the current short-term trend, the stock is expected to rise 24.34% during the next 3 months and, with a 90% probability hold a price between $67.67 and $80.92 at the end of this 3-month period.
Is Haemonetics a buy right now?
8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last twelve months. There are currently 3 hold...
How has Haemonetics' stock price been impacted by COVID-19 (Coronavirus)?
Haemonetics' stock was trading at $103.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Org...
Are investors shorting Haemonetics?
Haemonetics saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 1,800,000 shares,...
When is Haemonetics' next earnings date?
Haemonetics is scheduled to release its next quarterly earnings announcement on Thursday, May 12th 2022. View our earnings forecast for Haemonetics .
How were Haemonetics' earnings last quarter?
Haemonetics Co. (NYSE:HAE) issued its earnings results on Tuesday, February, 8th. The medical instruments supplier reported $0.84 EPS for the quart...
What guidance has Haemonetics issued on next quarter's earnings?
Haemonetics updated its FY 2022 earnings guidance on Tuesday, February, 22nd. The company provided earnings per share guidance of $2.450-$2.550 for...
What price target have analysts set for HAE?
8 analysts have issued 12-month price targets for Haemonetics' stock. Their forecasts range from $59.00 to $86.00. On average, they anticipate Haem...
Who are Haemonetics' key executives?
Haemonetics' management team includes the following people: Christopher A. Simon , President, Chief Executive Officer & Director ( LinkedIn Prof...
What is Christopher Simon's approval rating as Haemonetics' CEO?
48 employees have rated Haemonetics CEO Christopher Simon on Glassdoor.com . Christopher Simon has an approval rating of 63% among Haemonetics' em...
Recently Viewed Tickers
Haemonetics Corp
Visit a quote page and your recently viewed tickers will be displayed here.
Is Haemonetics a buy right now?
Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems.
What stocks does MarketBeat like better than Haemonetics?
8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock.
Are investors shorting Haemonetics?
Wall Street analysts have given Haemonetics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Haemonetics wasn't one of them.
When is Haemonetics' next earnings date?
Haemonetics saw a increase in short interest during the month of August. As of August 13th, there was short interest totaling 2,250,000 shares, an increase of 23.0% from the July 29th total of 1,830,000 shares. Based on an average daily volume of 732,200 shares, the short-interest ratio is currently 3.1 days.
How were Haemonetics' earnings last quarter?
Haemonetics is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.#N#View our earnings forecast for Haemonetics.
How has Haemonetics' stock been impacted by COVID-19 (Coronavirus)?
Haemonetics Co. (NYSE:HAE) announced its quarterly earnings data on Tuesday, August, 10th. The medical instruments supplier reported $0.50 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.45 by $0.05.
What guidance has Haemonetics issued on next quarter's earnings?
Haemonetics' stock was trading at $103.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, HAE stock has decreased by 34.9% and is now trading at $67.47.#N#View which stocks have been most impacted by COVID-19.
Key Earnings Data
Haemonetics issued an update on its FY 2022 earnings guidance on Wednesday, September, 8th. The company provided EPS guidance of $2.600-$3.000 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.780.
Haemonetics (HAE) Q1 Earnings and Revenues Top Estimates
Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.
